Portal de Periódicos da CAPES

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

2017; National Comprehensive Cancer; Volume: 15; Issue: 8 Linguagem: Inglês

10.6004/jnccn.2017.0131

1540-1413

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud M. Al-Hawary, Horacio J. Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson, Ellen F. Binder, Dana Backlund Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian G. Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey M. Hardacre, William G. Hawkins, Joseph M. Herman, Andrew H. Ko, Srinadh Komanduri, Albert C. Koong, Noelle K. LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O’Reilly, Jorge Obando, Sushanth Reddy, Courtney L. Scaife, Sarah P. Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer L. Burns, Susan Darlow,

Renal cell carcinoma treatment

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.